Publications by authors named "A Safi"

Novel species of fungi described in this study include those from various countries as follows: , from accumulated snow sediment sample. , on leaf spots of . , on submerged decaying wood in sea water, on , as endophyte from healthy leaves of .

View Article and Find Full Text PDF

Breast and prostate cancer are among the most commonly diagnosed cancers worldwide. Recent advances in tumor sequencing and gene studies have led to a paradigm shift from treatment centered on the type of tumor to therapy more focused on specific immune phenotype markers and molecular alterations. In this review, we discuss the utility and function of talazoparib concerning prostate cancer treatment and summarize recent and planned clinical trials on talazoparib.

View Article and Find Full Text PDF

Background: In this review, the complicated landscape of breast cancer management is explored with a focus on the promising synergies between ribociclib and endocrine therapy. Ribociclib mainly acts as a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, which disrupts cell cycle progression necessary for tumor growth. This, in combination with endocrine therapy, aims to produce hormone receptor-positive breast cancers, which is a very relevant subtype with challenging therapeutics.

View Article and Find Full Text PDF

Background: Facial implants have emerged as pivotal tools for both reconstructive and aesthetic skull bone augmentation. Contemporary manufacturing techniques, such as computer-aided design and manufacturing (CAD-CAM) systems, have revolutionized facial implants production, providing the advantages of high-level individualization. However, the absence of standardized facial measurements complicates the ability to accurately compare outcomes across various techniques.

View Article and Find Full Text PDF
Article Synopsis
  • Cancer is predicted to rise significantly, with 35 million new cases expected by 2050, mainly impacting low- and middle-income countries, particularly in the SAARC region.
  • There is a research investment and output gap in SAARC countries compared to high-income nations, leaving a lack of local studies and clinical trials in crucial areas like targeted therapy and immunotherapy.
  • Addressing the challenges of healthcare access, cultural and economic barriers, and limited funding in SAARC countries requires collaboration, improved research infrastructure, and local studies to develop practical and affordable cancer treatments.
View Article and Find Full Text PDF